Explain the following human genetic diseases :
(i) Haemophilia
(ii) Thalassemia
20 marks · directive: Explain
The core of a good answer
Haemophilia is an X-linked recessive bleeding disorder caused by deficiency of clotting factor VIII (haemophilia A) or IX (haemophilia B), so it affects mainly males; thalassaemia is an autosomal recessive disorder of reduced alpha- or beta-globin chain synthesis (genes on chromosomes 16 and 11) that causes anaemia ranging from silent carrier to transfusion-dependent thalassaemia major.
An outline written by upsc.help, not an official UPSC answer; every fact checked by a separate review. How we work
What the question asks
Each disease carries 10 marks: give cause, inheritance (with a cross), clinical features, diagnosis, treatment and prevention. Pedigree or Punnett-square sketches are expected for both.
Answer outline
Introduction
Both are single-gene disorders of the blood.
Haemophilia: cause and types
- Haemophilia A: deficient factor VIII (about 1 in 5,000 to 10,000 male births); haemophilia B (Christmas disease): factor IX (about 1 in 40,000); haemophilia C: factor XI, autosomal.
- Genes for factors VIII and IX lie on the X chromosome.
Haemophilia: inheritance
- X-linked recessive: carrier mother (XᴴXʰ) × normal father (XᴴY) gives half of sons affected and half of daughters carriers.
- Affected father passes the gene to all daughters (carriers) and no sons.
- Queen Victoria passed haemophilia B through her children into European royal families.
Haemophilia: features and management
- Prolonged bleeding after injury; spontaneous bleeding into joints (haemarthrosis) and muscles causing joint damage.
- Severity by factor activity: severe below 1%, moderate 1 to 5%, mild 5 to 40%.
- Diagnosis: prolonged activated partial thromboplastin time, factor assays.
- Treatment: factor replacement, desmopressin in mild A, emicizumab for A; gene therapies approved (Hemgenix for B, 2022).
Thalassaemia: cause and types
- Reduced or absent globin chain synthesis; autosomal recessive.
- Alpha thalassaemia: four alpha genes (HBA1, HBA2) on chromosome 16; one faulty copy silent carrier, two trait, three HbH disease, four Hb Bart's hydrops fetalis (usually fatal).
- Beta thalassaemia: HBB gene on chromosome 11; minor (one faulty gene, mild), intermedia, major (Cooley's anaemia, no functional beta chains).
Thalassaemia: features and management
- Major: severe anaemia from early childhood, jaundice, enlarged spleen, bone deformities from marrow expansion, iron overload.
- Diagnosis: blood count with small pale cells, haemoglobin electrophoresis or HPLC (HbA2 above about 3.5% in beta trait), DNA tests, prenatal diagnosis.
- Treatment: regular transfusion with iron chelation (deferoxamine, deferiprone, deferasirox), luspatercept, stem cell transplant (curative), gene therapy (Zynteglo, Casgevy).
- Prevention: carrier screening and counselling; Cyprus reduced affected births from 1 in 158 to nearly zero.
Common points
- Carriers of thalassaemia have some protection against malaria, which helps explain why the genes persist in malaria-affected regions.
Conclusion
Both diseases show how a single gene defect produces lifelong illness; carrier screening can prevent thalassaemia births, and gene therapies are now approved for both.
Examples and data to cite
- Global Burden of Disease 2021: about 1.31 million people have severe thalassaemia and 358 million carry the trait.
- Roughly 1.5% of the world population (80 to 90 million) carries a beta-thalassaemia gene.
Facts to remember
- Haemophilia A and B are X-linked recessive; females are rarely severely affected.
- Alpha-globin genes are on chromosome 16; beta-globin (HBB) on chromosome 11.
- Hb Bart's hydrops fetalis results from loss of all four alpha genes.
- Normal HbA2 is about 2.5 to 3.5%; it is raised in beta-thalassaemia trait.